Press Releases

Press Releases

Press Releases

Date Title and Summary Additional Formats
Dec 19, 2018
NICE Expands Recommendation for the Oncotype DX Breast Recurrence Score® Test to More Patients with Early-Stage Breast Cancer Within the United Kingdom
- Only test recommended based on its ability to predict chemotherapy benefit - Recommendation expanded to include patients with micrometastatic disease REDWOOD CITY, Calif. , Dec. 19, 2018 /PRNewswire/ --  Genomic Health, Inc. (NASDAQ: GHDX) today announced that the National Institute for Health
Dec 18, 2018
Genomic Health to Present at the 37th Annual J.P. Morgan Healthcare Conference
REDWOOD CITY, Calif. , Dec. 18, 2018 /PRNewswire/ -- Genomic Health, Inc. (NASDAQ: GHDX) today announced that Kim Popovits , chairman of the board, chief executive officer and president, will present at the 37 th Annual J.P. Morgan Healthcare Conference at the Westin St.
Dec 10, 2018
Multiple Oncotype DX Study Presentations at the 2018 San Antonio Breast Cancer Symposium Reinforce Real-world Value of the Oncotype DX Breast Recurrence Score® Test in Patients Regardless of Age or Race
REDWOOD CITY, Calif. , Dec. 10, 2018 /PRNewswire/ -- Genomic Health, Inc. (NASDAQ: GHDX) today announced results from multiple Oncotype DX Breast Recurrence Score ® (RS) presentations at the 2018 San Antonio Breast Cancer Symposium ® (SABCS), reinforcing the value of the Oncotype DX ® test in
Dec 03, 2018
Genomic Health and Biocartis Expand Collaboration to Urology with the Development of an Idylla™ Oncotype DX® Genomic Prostate Score® Test
REDWOOD CITY, Calif. and MECHELEN, Belgium , Dec. 3, 2018 /PRNewswire/ --  Genomic Health , Inc. (NASDAQ: GHDX), the world's leading provider of genomic-based diagnostic tests and Biocartis Group NV, an innovative molecular diagnostics company (Euronext Brussels: BCART), today announced they have
Nov 29, 2018
New Analysis of NSABP Randomized B-20 Study Confirms Patients with Oncotype DX Breast Recurrence Score® Results Greater Than 25 Have Life-saving Benefit from Chemotherapy, Reinforcing the Conclusions of the Landmark TAILORx Study
Published Results Underscore Value of Oncotype DX® Test in Identifying Women with Early-stage Breast Cancer Who May Receive Life-saving Benefit from Chemotherapy REDWOOD CITY, Calif. , Nov. 29, 2018 /PRNewswire/ -- Genomic Health , Inc.  (NASDAQ: GHDX)  and the NSABP Foundation today announced the
Nov 19, 2018
Genomic Health Announces Presentation of Two Large Studies at the 2018 San Antonio Breast Cancer Symposium, Reinforcing Real-world Value of the Oncotype DX Breast Recurrence Score® Test
REDWOOD CITY, Calif. , Nov. 19, 2018 /PRNewswire/ -- Genomic Health, Inc. (NASDAQ: GHDX) today announced that it will present results from two large studies of the Oncotype DX Breast Recurrence Score ® test at the 2018 San Antonio Breast Cancer Symposium ® (SABCS), which will be held December 4-8 .
Nov 08, 2018
Genomic Health to Present at the 2018 Canaccord Genuity Medical Technologies & Diagnostics Forum
REDWOOD CITY, Calif. , Nov. 8, 2018 /PRNewswire/ -- Genomic Health, Inc. (NASDAQ: GHDX) today announced that it will present at the 2018 Canaccord Genuity Medical Technologies and Diagnostics Forum in New York City on Thursday, November 15, 2018 at 9:30 a.m. Eastern Time .
Nov 06, 2018
Genomic Health Announces Record Revenue and Profit in Third Quarter 2018 Financial Results; Raises Full Year Guidance
REDWOOD CITY, Calif. , Nov. 6, 2018 /PRNewswire/ -- Genomic Health , Inc. (NASDAQ: GHDX) today reported financial results and business progress for the quarter ended September 30, 2018 . "We continue to deliver record results in 2018, including 23 percent revenue growth and $12 million in profit
Oct 30, 2018
Genomic Health to Announce Third Quarter 2018 Financial Results and Host Conference Call on Tuesday, November 6, 2018
REDWOOD CITY, Calif. , Oct. 30, 2018 /PRNewswire/ -- Genomic Health, Inc. (NASDAQ:  GHDX) today announced that the company will host a conference call and webcast on Tuesday, November 6 at 4:30 p.m. Eastern Time to discuss its third quarter 2018 financial results.
Oct 29, 2018
Medicare Establishes Final Local Coverage Determination (LCD) for Use of the Oncotype DX® AR-V7 Nucleus Detect™ Test in Patients with Metastatic Castrate Resistant Prostate Cancer Effective December 10
Medicare coverage supports clinical utility of the Oncotype DX AR-V7 Nucleus Detect test, providing 25,000 Medicare patients with coverage SAN DIEGO and REDWOOD CITY, Calif. , Oct. 29, 2018 /PRNewswire/ --  Epic Sciences, Inc. (Epic) and Genomic Health, Inc.